The benefits of fixed combinations for the treatment of arterial hypertension in women with menopausal disorders: focus on Gipotef


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Arterial hypertension (AH) is a risk factor for the development of severe cardiovascular complications. During menopause, women have poor control of blood pressure (BP) and an increased risk of cardiovascular complications. Description of the clinical case. This article discusses the clinical case of a patient L. 51 years old, who complained of periodic headaches (especially against the background of physical and psycho-emotional stress), frequent dizziness, “noise and ringing" in the ears, severe fatigue during physical and emotional stress, periodic mild forgetfulness, leading to a decrease in mental performance, disorganization that interferes with the implementation of professional activities. The patient was in menopause for 2 years. Based on complaints, as well as data of physical examination, instrumental and laboratory tests, the diagnosis of second stage arterial hypertension, 2nd degree, high risk (risk 3) was established. The target blood pressure for this patient, taking into account her age and the absence of chronic kidney disease, is 120-129/70-79 mm Hg. The patient received therapy with the combined drug Gipotef. After 3 weeks of taking Gipotef, the patient reached the target blood pressure values, the daily profile of her blood pressure returned to normal; she noted a regression of headaches, an improvement in overall well-being, increased performance, the disappearance of a sensation of “noise and ringing" in the ears, greater concentration, less distraction. Conclusion. Thus, Gipotef had a complex effect: it effectively lowered blood pressure, improved the quality of life and contributed to the prevention of cardiovascular risks in a patient with arterial hypertension and menopausal disorders.

Full Text

Restricted Access

About the authors

Olga D. Ostroumova

Russian Medical Academy of Continuous Professional Education

Email: ostroumova.olga@mail.ru
Professor, Dr. Sci. (Med.), Professor of the Department of Therapy and Polymorbid Pathology Moscow, Russia

A. P Pereverzev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

S. V Batyukina

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

References

  1. Williams B., Mancia G., Spiering W., et a!., ESC Scientific Document Group, 2018 ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 2018;39(33):3021-104. https://doi. org/10.1093/eurheartj/ehy339.
  2. Lima R., Wofford M., Reckelhoff J.F. Hypertension in postmenopausal women. Curr Hypertens Rep. 2012;14(3):254-60. doi: 10.1007/s11906-012-0260-0.
  3. Ong K.L., Tso A.W.K., Lam K.S., Cheung B.M. Gender differences in BP control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008;51:1142-48
  4. Wiinberg N., H0egholm A., Christensen H.R., et al. 24-h ambulatory BP in 352 normal Danish subjects, related to age and gender. Am J Hypertension. 1995;8:978-86.
  5. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. results from the Third National Health and Nutrition Examination Survey 1988-1991. Hypertension. 1995;25:305-13.
  6. National Center for Health and Statistics Health, United States, 2010, with special feature on death and dying. 2011Hyattsville MDData Tables: 67.
  7. Kearney P.M., Whelton M., Reynolds K, et al. Global burden of hypertension; analysis of worldwide data. Lancet. 2005;365:217-23.
  8. Taddei S. BP through aging and menopause. Climacteric. 2009;12(Suppl. 1):36-40.
  9. Perez-Lopez F.R., Chedraui P., Gilbert J.J., Perez-Roncero G. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. Fertil Steril. 2009;92:1171-86.
  10. Sjoberg L., Kaaja R., Tuomilehto J. Epidemiology of postmenopausal hypertension. Int J Clin Pract. Suppl. 2004;139:4-12.
  11. Kim J.K., Alley D., Seeman T., et al. Recent changes in cardiovascular risk factors among women and men. J. Women's Health (Larchmont). 2006;15:734-46.
  12. Karmakar N., Majumdar S., Dasgupta A., Das S. Quality of life among menopausal women: A community-based study in a rural area of West Bengal. J Midlife Health. 2017;8(1):21-7. doi: 10.4103/jmh.JMH_78_16.
  13. Женщины и мужчины России 2018. Статистический сборник Росстат. М., 2018. 241 с.
  14. Сметник В.П. Медицина климактерия. Ярославль, 2006. 848 c
  15. Официальный сайт Всемирной организации здравоохранения. URL: https://www.who.int (дата обращения/date of access: 27.03.2020)
  16. Пахомов А.А., Рухляда Н.Н., Бакина Н.Н. и др. Психофизиологические особенности женщин в климактерическом периоде. Ученые записки университета им. П.Ф. Лесгафта. 2011;10(80):159- 63
  17. Балан В.Е., Вихляева Е.М., Зайдиева Я.3. и др. Менопаузальный синдром (клиника, диагностика, профилактика и заместительная гормональная терапия). М., 1996. 64 с
  18. Подзолков В. И., Брагина А.Е., Радионова В.Н. и др. Центральные и гуморальные механизмы формирования артериальной гипертензии у женщин. Системные гипертонии. 2015;1:7682
  19. Подзолков В.И., Брагина А.Е. Эссенциальная артериальная гипертензия у женщин или женская артериальная гипертензия. Кардиоваскулярная терапия и профилактика. 2012;11(1):79-84
  20. Rosano G.M., Vitale C., Fini M. Hypertension in Postmenopausal Women. URL: https://www. touchendocrinology.com/wp-content/uploads/ sites/5/2015/06/rosano.pdf. Doi: 10.17925/ EE.2006.00.01.69.
  21. Thorp A.A., Schlaich M.P Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. J Diab Res. 2015;2015:341583. doi: 10.1155/2015/341583.
  22. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61(236):1081-90.
  23. Esler M., Rumantir M., Wiesner G., et al. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertension. 2001;14(11 Pt. 2):304-9.
  24. Lambert G.W., Straznicky N.E., Lambert E.A., et al. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126(2):159-72. Doi: 10.1016/j. pharmthera.2010.02.002.
  25. Muntzel M.S., Morgan D.A., Mark A.L., Johnson A.K. intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity Am J Physiol. 1994;267(5 Pt. 2):R1350-doi: 10.1152/ajpregu.1994.267.5.R1350.
  26. Kwasniewska M., Pikala M., Kaczmarczyk-Chafas K., et al. Smoking status, the menopausal transition, and metabolic syndrome in women. Menopause. 2012;19:194-200.
  27. Kozakowski J., Gietka-Czernel M., Leszczynska D., Majos A. Obesity in menopause - our negligence or an unfortunate inevitability? Prz Menopauzalny. 2017;16(2):61-5. Doi: 10.5114/ pm.2017.68594.
  28. Рубрикатор клинических рекомендаций Минздрава России. URL: http://cr.rosminzdrav.ru (дата обращения/date of access: 01.04.2020).
  29. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404-23
  30. Issa Z., Seely E.W., Rahme M., El-Hajj Fuleihan G. Effects of hormone therapy on blood pressure. Menopause. 2015;22:456-68.
  31. Горбунов В.М., Деев А.Д., Платонова Е.В., Быстрова М.М. Сравнительная оценка эффективности эналаприла и дилтиазема у женщин с артериальной гипертонией в период менопаузы. РФК. 2007;4
  32. Preston R.A., Alonso A., Panzitta D., et al. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertension. 2002;15:816-22.
  33. Preston R.A., White W.B., Pitt B., et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertension. 2005;18:797-804.
  34. White W.B., Pitt B., Preston R.A., Hanes V. Antihypertensive effects of drospirenone with 17-beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112:1979-784.
  35. Olsson G., Wikstrand J., Warnold I., et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13:28-32.
  36. Zang Y., Tan Q., Ma X., et al. Osteogenic actions of metoprolol in an ovariectomized rat model of menopause. Menopause. 2016;23(9):1019-25. doi: 10.1097/GME.0000000000000680.
  37. Tella S.H., Gallagher J.C. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-70. Doi: 10.1016/j. jsbmb.2013.09.008.
  38. Государственный реестр лекарственных средств Российской Федерации. URL: http://grls. rosminzdrav.ru (дата обращения 01.04.2020).
  39. SPC indap, verze 3.10.2012.
  40. SPC indapamid PMCS, verze 14.3.2012.
  41. Sweetman S.C. Martindale. The Complete Drug Reference. 37th ed. 1445 p.
  42. Brunnton L., et al. Goodman and Gilmans's. The Pharmacological Basis of Therapeutics. 12th ed. P. 686-90.
  43. Lullmann H., et al. Farmakologie a toxikologie. Vyd. 2. ceske vydani. Praha: Grada Publishing, 2004. 255 p.
  44. Wacher B., et al. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Exp Opin Pharmacother. 2012;13(10):1515-26.
  45. Noboru T. indapamide as an antihypertensive agent. Progr Hypertension. 1991;2:269-89.
  46. Campbell D.B., Brackman F. A Symposium:Indapamide and Antihypertensive Strategy. Cardiovascular Protective Properties of indapamide. Am J Cardiol. 1990;65(17):11H-27.
  47. Suchopar J., et al. Remedia. Vyd. 4. Praha: Panax Co, spol. s r.o., 2009. 96p.
  48. Diagnosticke a lecebne postupy u arterialni hypertenze - verze 2012. Vnitr Lek. 2012;58(10):785-801.
  49. ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34(28):2159-219.
  50. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease PROGRESS Collaborative Group. Eur Heart J. 2003; 24:475-84.
  51. Vitovec J., Spinar J. Perindopril/indapamid - fixni kombinace. Remedia. 2007;17:247-57.
  52. Firas J., et al. Evidence-based diuretic therapy for improving cardiovascular prognosis in systemic hypertension. Am J Cardiol. 2011;107(8): 1178-84.
  53. Asmar A., et al. Efficacy and tolerance of indapamide sustained release 1,5 mg on 24-h blood pressure in essentials hypertension. Eur Heart J. 999;(Suppl. 1):21-30.
  54. Schiavi F.I., et al. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Clin Pharmacol. 2000; 14:139-46.
  55. Ambrosioni E., et al. Low dose antihypertensive therapy with sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertension. 1998;16:1677-84.
  56. Roush G.C., Ernst M.E., Kostis J.B., et al. Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects. Hypertension. 2015;65(5):1041-46. Doi: 10.1161/ hypertensionaha.114.05021.
  57. Руководство по артериальной гипертонии. Под ред. Е.И. Чазова, И.Е. Чазовой. М., 2005.
  58. Чазова И.Е., Недогода С.В., Жернакова Ю.В. и др. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями. Кардиологический вестник. 2014;IX(1):357
  59. Люсов В.А., Харченко В.И., Евсиков Е.М. и др. Насколько часто возможно развитие гипокалиемии при лечении индапамидом? Российский кардиологический журнал. 2008;1(69):50-6
  60. Gosse P., Sheridan D.J., Zannad F., et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study J Hypertension. 2000;18(10): 1465-75. doi: 10.1097/00004872-200018100-00015.
  61. Marre M., Puig J.G., Kokot F., et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertension. 2004;22(8):1613-22. doi: 10.1097/01. hjh.0000133733.32125.09.
  62. Beckett N.S., Peters R., Fletcher A.E., et al., for the HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med. 2008;358:1887-98. Doi: 10.1056/ NEJMoa0801369.
  63. Gavras H. A. multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther. 1986;9(1):24-38.
  64. Wright J.W, Bakris G., Greene T., et al, for the AASK Collaborative Research Group. Effect of blood pressure lowering and antihypertensive class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31
  65. Евдокимова А.Г и др. Клиническая эффективность комбинированной антигипертензивной терапии в фиксированных дозах: фокус на Гипотэф. Терапия. 2016;6(10);68-78.
  66. Шишкова В.Н., Капустина Л.А. Новые возможности терапии артериальной гипертензии у женщин в менопаузе. Лечащий врач. 2019;7:2-16
  67. Скотников А.С., Хамурзова М.А. Органопротективные свойства гипотензивной терапии как профилактика развития «сосудистой» коморбидности. Лечащий врач. 2017;7:16-24
  68. Скотников А.С., Хамурзова М.А. Новые комбинации для комплексного лечения артериальной гипертензии в помощь врачу общей практики. Поликлиника. Кардиолог сегодня. Спецвыпуск 2017/2018;1:47-55
  69. Скотников А.С., Юдина Д.Ю., Стахнев Е.Ю. Гипотензивная терапия коморбидного больного: на что ориентироваться в выборе лекарственного средства? Лечащий врач. 2018;2:2430
  70. Мамедов М.Н. Новый взгляд на стартовую терапию артериальной гипертонии у работающего пациента: практические аспекты концепции «полипилл». Лечебное дело. 2017;3:26-30
  71. Мамедов М.Н., Угурчиева П.О., Дидигова Р.Т. Пациент с артериальной гипертонией, коморбидностью и высоким сердечно-сосудистым риском: обоснованность назначения многокомпонентной антигипертензивной терапии. Лечебное дело. 2019;3:62-5
  72. Verdecchia P., Angeli F., Gattobigio R., et al. Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Com+plications in Hypertension. Am J Hypertension. 2007;20:154-61.
  73. Mancia G., Bombelli M., Facchetti R., et al. Longterm prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study Hypertension. 2007;49:1265-70.
  74. Verdecchia P, Schillaci G., Boldrini F, et al. Blunted Nocturnal Fall in Blood Pressure in Hypertensive Women with Future Cardiovascular Events. Circulation 1992;86(Suppl.1):678 Abstract.
  75. Imai Y., Tsuji I., Nagai К., et al. Circadian blood pressure variation related to morbidity and mortality from cerebrovascular and cardiovascular diseases. Ann N Y Асad Sci. 1996;783:172-85.
  76. Ohkubo T., Imai Y. Tsuji I., et al. Relation between nocturnal decline in blood pressure and mortality The Ohasama Study Am J Hypertension. 1997;10:1201-207.
  77. Rothwell P., Howard S.C., Dolan E., et al. Prognostic signi cance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet. 2010;375(9718):895-905. doi: 10.1016/S0140-6736 (10)60308-X.
  78. Hocht C. Blood pressure variability: prognostic value and therapeutic implications. ISRN Hypertension. 2013;2013:ID 398485.
  79. Parati G., Pomidossi G., Albini F., et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertension. 1987;5(1):93-8.
  80. Mancia G., Parati G., Hennig M., et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertension. 2001;19(11):1981-89.
  81. Sega R., Corrao G., Bombelli M., et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study. Hypertension. 2002;39(2):710-14.
  82. McMullan C.J., Bakris G.L., Phillips R.A., Forman J.P. Association of blood pressure variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013;8(5):731-38.
  83. Kawai T., Ohishi M., Kamide K. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertens Res. 2013;36:232-39.
  84. Schillaci G., Bilo G., Pucci G., et al. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: ndings from 2 large databases. Hypertension. 2012;60(2):369-77. Doi: 10.1161/ HYPERTENSIONAHA.112.197491.
  85. Schutte A.E., Schutte R., Huisman H.W., et al. Blood pressure variability is signi cantly associated with ECG left ventricular mass in normotensive Africans: The SABPA Study. Hypertens Res. 2011;34(10):1127-34.
  86. Sakakura K., Ishikawa J., Okuno M., et al. Exaggerated ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly. Am J Hypertension. 2007;20(7):720-27.
  87. Dahlof B., Sever P.S., Poulter N.R., et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366(9489):895-906.
  88. Stolarz-Skrzypek K., Thijs L., Richart T., et al. Blood Pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertension Res. 2010;33:757-66.
  89. Eguchi К., Hoshide S., Schwartz J.E., et al. Visit-to-visit and Ambulatory Blood Pressure Variability as Predictors of Incident Cardiovascular Events in Patients with Hypertension. Am J Hypertension. 2012;25(9): 962-68. Doi: 10.1038/ ajh.2012.75.
  90. Matyi J.M., Rattinger G.B., Schwartz S., et al. Lifetime estrogen exposure and cognition in late life. the Cache County Study. Menopause. 2019;26(12):1366-74. Doi: 10.1097/ GME.0000000000001405.
  91. Johnson K., Margolis K., Espeland M., et al. Women's Health Initiative Memory Study and Women's Health Initiative Investigators. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. J Am Geriatr Soc. 2008;56:1449-58.
  92. Elias P., D'Agostino R., Elias M., et al. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp Aging Res. 1995;21:393-417.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies